Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Ovarian Neoplasms

Free Subscription 22.12.2025 2 Am J Surg Pathol 1 BMC Cancer 1 Cancer Chemother Pharmacol 1 Clin Cancer Res 1 Gynecol Oncol 1 Histopathology 3 Int J Gynecol Pathol 1 Oncogene

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. BOYRAZ B, Young RH, Oliva E, Devins KM, et al
   Anaplastic Juvenile Granulosa Cell Tumor: A Report of 10 Cases of an Unemphasized Variant With Adverse Prognostic Features Characterized by TP53 Inactivation With MYC Family Amplifications.
   Am J Surg Pathol. 2026;50:62-73.
   PubMed         Abstract available
   
   
2. WILLIAMS JF, Glomski K, Ulbright TM, Hanley KZ, et al
   SOX2 Is the Most Sensitive Biomarker in Testicular and Gynecologic Embryonic-type Neuroectodermal Tumors (ENT) Based on a Comprehensive Evaluation of Biomarker Expression.
   Am J Surg Pathol. 2025 Sep 10. doi: 10.1097/PAS.0000000000002466.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. LI Y, Chen X, Xu Y, Huang S, et al
   Long noncoding RNA BMPR1B-DT promotes anoikis and reduces proliferation in ovarian cancer.
   BMC Cancer. 2025 Dec 18. doi: 10.1186/s12885-025-14656.
   PubMed         Abstract available
   
   

   
   Cancer Chemother Pharmacol

4. HARLEV C, Petersen EK, Bue M, Petersen LK, et al
   Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model.
   Cancer Chemother Pharmacol. 2025;95:125.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

5. ZOELLER JJ, Tammali R, Dodd RB, Patel NV, et al
   Derivation of AZD5335, a Novel FRalpha-Targeted TOP1i-Loaded ADC, for the Treatment of FRalpha-Expressing Cancers.
   Clin Cancer Res. 2025;31:5261-5275.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

6. LESNOCK J, Gaillard S, Tew WP
   ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
   Gynecol Oncol. 2025;204:251-253.
   PubMed        
   
   

   
   Histopathology

7. DE BOECK A, Kang EY, Meagher NS, Gorringe KL, et al
   A 5-marker immunohistochemical panel of CK17, MEP1A, PAX8, SMAD4, and CDX2 to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma.
   Histopathology. 2026;88:402-413.
   PubMed         Abstract available
   
   

   
   Int J Gynecol Pathol

8. LIANG B, Tenney TB, Han L, Zhang X, et al
   Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma.
   Int J Gynecol Pathol. 2026;45:9-17.
   PubMed         Abstract available
   
   
9. GUPTA A, Gupta N, Srinivasan R, Rai B, et al
   Ovarian Teratomas Unveiled: Pathologists' Curiosity Reveals Intriguing Associations in the Enigmatic Realm.
   Int J Gynecol Pathol. 2026;45:44-51.
   PubMed         Abstract available
   
   
10. GUDU W, Berhane B, Urgie T, Dereje B, et al
    Implementation of Frozen Section Services for Gynecologic Surgeries in a Single Institution in Ethiopia: Results of a Pilot 12-Month Experience and Implications for Introduction into Low- and Middle-Income Countries.
    Int J Gynecol Pathol. 2026;45:52-56.
    PubMed         Abstract available
    
    

    
    Oncogene

11. JI F, Yan K, Ding B, Zhu Y, et al
    Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
    Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.